Background. Current knowledge about the natural history, treatment and physicians' perception of chronic allograft nephropathy (CAN) is limited. The present study evaluated the prevalence and determinants of CAN in renal transplant patients. Methods. Epidemiological, cross-sectional multi-centre study conducted in Spain. A total of 872 renal transplant recipients with a functioning graft and at least 2 years of post-transplant data on renal function were consecutively included. CAN diagnosis was recorded based on physician's clinical criteria and on laboratory criteria (serum creatinine !2 mg/dL and/ or glomerular filtration rate 50 mL/min). Results. The mean time from transplantation until the time of this study was 8.2 years. CAN was diagnosed in 35% of patients (n ¼ 305) according to the physician's criteria (31% of whom with histological assessment) and in 55.5% (n ¼ 482) according to laboratory objective criteria. An older donor age, lack of induction therapy, cyclosporine use, lower tacrolimus levels at 1 year, acute rejection, hypertension and worse initial renal function were associated with CAN development. Time from transplant to biopsy was greater in patients with anti-proteinuric treatment. Immunosuppression was modified in 46.9% of patients with CAN diagnosis [calcineurin inhibitor (CNI) reduction alone in 18.9% of cases; CNI reduction and mycophenolate modification in 17.8% and CNI reduction or withdrawal with introduction of proliferation signal inhibitors in 12.9%). Conclusions. After~8 years from renal transplantation, 55.5% of patients presented CAN, which was considerably underestimated by physicians. An older donor age and less initial immunosuppression seemed to be related to CAN development.
Introduction
Renal transplantation is the treatment of choice of endstage renal disease (ESRD) with high short-term graft survival but with permanent attrition in the long term. Complications affecting the lifespan of the graft and quality of life of the patient are still common during the posttransplant period [1] . In renal transplantation (RT), despite ever-improving immunosuppression, chronic allograft nephropathy (CAN) remains the main cause of graft loss: 40% of renal graft losses are attributable to CAN [2, 3] .
CAN is characterized by a progressive deterioration of renal function with interstitial fibrosis and tubular atrophy which leads to proteinuria, high blood pressure and a progressive increase in serum creatinine. Nankivell et al. [4] demonstrated that all protocol renal biopsies 3 years after renal transplantation showed evidence of some degree of CAN, and that, at 5 years post-transplantation, 93.5% of patients had evidence of cyclosporine nephrotoxicity and 65% had moderate or severe CAN. Several studies using routine biopsies suggest that CAN diagnosis is underestimated when serum creatinine alone is used to diagnose the condition [3] [4] [5] [6] .
The aetiology of CAN is not completely understood, but it appears to be a progressive and time-dependent condition [5] . Related factors have been divided into immune and non-immune. Immune factors include cellular-or antibody-mediated response, which resolves in acute or chronic rejection [5] . Non-immune factors include ischaemia-reperfusion injury, patient co-morbidities (i.e. high blood pressure, hyperlipidaemia, proteinuria, hyperfiltration and infections) and calcineurin inhibitors (CNI) nephrotoxicity [7] . A degree of synergism between the identified risk factors for CAN appears to exist [5] .
The present study was designed to determine the prevalence of CAN among maintenance renal transplant patients according to objective laboratory criteria. Additionally, the study aimed to assess differences between physician's perception of CAN and diagnosis according to objective functional criteria; to investigate the determinants of CAN development and of biopsy performance in the clinical practice; to describe the evolution in renal function in patients with and without CAN as well as to describe therapeutic decisions related to CAN diagnosis (immunosuppressive regimen and anti-proteinuric treatment).
Materials and methods
We conducted an observational, multi-centre cross-sectional study in 52 renal transplantation outpatient units in Spain. All recipients of a renal allograft with at least 2 years post-transplant data on renal function, aged !18 years and with a functioning graft were eligible for inclusion in the study. Patients were excluded if they had received a multi-organ transplantation. A systematic consecutive sampling was performed: following initiation of the study at each site in May 2007, patients fulfilling selection criteria were consecutively enrolled as they attended the centre for any reason. All patients signed the informed consent for their participation in the study. The study was approved by an Institutional Review Board and was adherent to the Declaration of Helsinki.
Data was obtained via personal interview of the patient and through medical records extraction. Relevant information included patient demographics and medical history, ESRD aetiology, transplant evolution, donor age and sex, recipient viral serologies (cytomegalovirus, hepatitis C virus and hepatitis B virus), induction therapy and immunosuppressive regimen at hospital discharge. A detailed post-transplant history was also obtained which included information on post-transplant medical history (i.e. acute rejection, diabetes, hypertension, malignancy), diagnosis of CAN and renal biopsies performed. Information on anti-proteinuric treatment [i.e. angiotensin-converting enzyme inhibitors (ACEs)/angiotensin receptor 2 antagonists] used was also collected. Additionally, detailed information on proteinuria, serum creatinine levels, glomerular filtration rate (GFR) and changes in the immunosuppressive treatment within the first year (at nadir serum creatinine), at 1, 3, 5 and 6 years post-transplant and at current visit was collected.
For the present study, CAN diagnosis was recorded based on physician's clinical criteria or based on laboratory criteria (cut-off points: serum creatinine !2 mg/dL and/or GFR 50 mL/min). Objective laboratory criteria of GFR ( 50 mL/min) was based on K-DOQI guidelines (lower range for Stage 3 renal dysfunction). GFR was estimated using the abbreviated Modification of Diet for Renal Diseases (MDRD) equation [8] . In the questionnaire, the physician was asked whether he considered the patient had CAN according to his perception. Every clinician was aware of objective cut-off points when answering the questionnaire.
A descriptive analysis was performed for the collected variables using data from all patients included in the study. Prevalences and associated 95% confidence interval (CI) of relevant variables were calculated. Kappa index was used to assess the concordance between clinician and functional objective established diagnostic criteria for CAN diagnosis. Chi-square tests and Student's t-tests were used to compare frequencies and means between subgroups with and without CAN according to the qualitative and quantitative variables, respectively. Stepwise unconditional logistic regression analysis, including creatinine, proteinuria and GFR, was performed to assess the determinants for conducting a biopsy in patients with diagnosed or suspected CAN. Creatinine slope from nadir, expressed as milligrams per deciliter per year, was calculated through minimum quadratic regression method. Mean times until CAN diagnosis in subgroups of patients defined by transplantation era (2007-03, 1999-2002, 1992 -98, before 1992) were estimated using Kaplan-Meier method. The relationship between year of transplantation and time until CAN diagnosis was evaluated using univariate and multivariate Cox regression models, adjusting for possible confounding factors. Data was analysed using SPSS 12.0 statistical package (SPSS Inc, Chicago, IL).
Results
A total of 872 patients were enrolled between May and June 2007, accounting for~5% of prevalent renal transplant patients in Spain on that date (according to the 2007 estimates of the National Registry [9] ). Table 1 shows the main characteristics of the study population. Chronic glomerulonephritis was the main cause for ESRD (32.7%). The mean time from transplantation until the time of this study was 8.2 years (SD ¼ 5.1), with current creatinine levels of 1.6 mg/dL (SD ¼ 0.7), proteinuria of 0.5 g/day (SD ¼ 1.0), GFR of 50.7 mL/min (SD ¼ 20.7), creatinine slope from nadir of 0.0 mg/dL/year (SD ¼ 0.2) and GFR slope of À0.1 mL/min/year (SD ¼ 4.6). No induction treatment was used in 61.9% of patients, anti-CD25 antibodies were administered to 19.2%, thymoglobulin to 14.6%, OKT3 to 2.2%, and it was unknown in 1.8%. Table 1 also shows the immunosuppressive treatment administered at transplantation discharge. The most commonly used drugs were prednisone (97.5%), mycophenolate mofetil (62%) and cyclosporine (51.6%). Table 2 shows the prevalence of CAN according to the diagnostic method (physician's clinical criteria and laboratory objective criteria) and the concordance between them. When the diagnosis was based on the physician's criteria, the observed prevalence of CAN was 35% (95% CI ¼ 31.8-38.1%) (n ¼ 305); when the pre-specified laboratory criteria were used, the prevalence of CAN was 55.5% (95% CI ¼ 52.2-58.5%) (n ¼ 482). The difference between prevalences was significant (P ¼ 0.0001). The resulting kappa index was 0.51 (95% CI ¼ 0.45-0.56). Among those that were classified as having CAN by laboratory criteria, 41.3% (n ¼ 199) had not been diagnosed with CAN based on the physician's criteria.
When creatinine >2 mg/dL alone was used as the cut-off objective value, the prevalence of CAN was 25.2% (n ¼ 219), and the concordance with the diagnosis according to clinical criteria was slightly higher (kappa index ¼ 0.59, 95% CI ¼ 0.54-0.65) than that obtained with double laboratory criteria (Table 2) . When the GFR criteria alone was applied ( 50 mL/min, n with CAN ¼ 482, prevalence of 55.5%), the kappa index was 0.51 (95% CI ¼ 0.45-0.56) (data not shown). Table 3 shows the main differences in clinical and laboratory values between patients with and without diagnosis of CAN. An older donor age, lack of induction therapy, cyclosporine use, lower tacrolimus levels at 1 year, acute rejection, hypertension and worse initial renal function were associated with CAN development. Figure 1 . The relationship between year of transplantation and time until CAN diagnosis was statistically significant in a multivariate Cox regression model (hazard ratio: 0.83 for each year earlier, 95% CI 0.80-0.87, P < 0.0005), after adjusting by post-transplant dyslipidaemia, hypertension, use of induction therapy, use of Csa-/Tac-based or other immunosuppression at discharge, episodes of acute rejection and donor age. All these confounding variables had different distribution according to transplantation era: more recently, transplanted patients had a higher prevalence of dyslipidaemia and hypertension, more use of induction therapy, especially anti-CD25, a higher use of tacrolimus-based regimens, a higher rate of acute rejection and older donor age (data not shown). a According to physician's clinical criteria. No significant differences were found between CAN and no CAN subgroups in the following variables: weight; donor sex; cause of ESRD; hyperlipidaemia; diabetes; ischaemic heart disease; time since transplantation; recipient viral serologies (CMV, HCV and HBV); prednisone, mycophenolate mofetil, azathioprine, sirolimus or enteric-coated mycophenolate sodium use at discharge; cyclosporine, mycophenolate mofetil, azathioprine or prednisone doses at 1 year; cyclosporine levels at 1 year (data not shown).
Among 305 patients diagnosed with CAN based on physician's criteria, 95 (31.1%) had had a biopsy performed due to suspicion of chronic dysfunction [in whom, according to laboratory criteria, CAN was present in 89.5% of cases (n ¼ 85)]. Severity of CAN in biopsied patients was: Grade I in 56.0%, Grade II in 34.7% and Grade III in 9.3%. Histological signs of calcineurin inhibitor toxicity were found in 12 patients (12.6%). Eighteen patients had had a biopsy performed due to other reasons, in whom acute tubular necrosis was found in 8 cases and IgA nephropathy in 7 cases.
At the time of CAN diagnosis based on physicians criteria, those patients with renal biopsy presented a higher mean serum creatinine level than those without biopsy [2.28 mg/dL (SD ¼ 0.69) versus 2.10 mg/dL (SD ¼ 0.43), respectively, P ¼ 0.0258], lower GFR [32.6 mL/ min (SD ¼ 12.8) versus 33.6 mL/min (SD ¼ 9.2), respectively, P ¼ 0.04687] and higher 24-h proteinuria [1.20 g/24 h (SD ¼ 1.6) versus 0.67 g/24 h (SD ¼ 0.8), respectively, P ¼ 0.0041]. In the stepwise logistic regression model, lower GFR and higher proteinuria were the most powerful and independent predictors of having a renal biopsy performed (data not shown).
The performance of a biopsy was not significantly associated with a change in the immunosuppressive regimen after CAN diagnosis: 53% of CAN patients without biopsy did not have their immunosuppressive treatment modified versus 45% of those who had a biopsy performed (P ¼ 0.250).
Among those patients with treatment modification at the time of CAN diagnosis (49.6%), the main changes were: reduction of calcineurin inhibitors alone, conducted in 18.9% of cases (21.5% in the subgroup with biopsy versus 13.7% in the subgroup without biopsy, P ¼ 0.118); suspension or reduction of calcineurin inhibitors and modification in mycophenolic acid administration, in 17.8% of cases (22.5% of CAN cases with biopsy versus 15.6% of cases without biopsy, P ¼ 0.189) and introduction of proliferation signal inhibitors (PSI), together with a reduction or withdrawal of calcineurin inhibitors, in 12.9% of cases (18.7% of CAN cases with biopsy versus 10.2% of cases without a biopsy, P ¼ 0.030). Therefore, with a common diagnosis of CAN, different therapeutic approaches were attempted.
The performance of a renal biopsy did not affect the introduction of anti-proteinuric treatment de novo with ACEs and/or angiotensin receptor blockers (ARBs) (antiproteinuric treatment was introduced in 39% of CAN cases with biopsy versus 35% of CAN cases without biopsy, P ¼ 0.470). However, among subjects who were already receiving ACE/ARB, the time to biopsy was longer than among those without ACE/ARB treatment (50.94 days versus 38.87 days, respectively, P ¼ 0.029). Table 4 shows the relationship between changes in the immunosuppressive treatment at CAN diagnosis and creatinine level and slope. Among those patients that underwent reduction or suspension of calcineurin inhibitors and introduction of sirolimus/everolimus, the slope and the mean level of serum creatinine were significantly higher than among those with other changes or without any change.
Discussion
Our findings suggest that chronic renal allograft nephropathy, according to an objective laboratory criterion, is present in 55.5% of renal recipients after~8e years of post-transplant follow-up. We tested two laboratory criteria: the serum creatinine level and the GFR calculated according to MDRD equation. As expected, the GFR cut-off level of 50 mL/min resulted in a wider criterion than the creatinine level !2 mg/dL, allowing to diagnose CAN in a significantly higher number of patients (also including all those who had been diagnosed by the creatinine level).
Regarding the concordance with the physician's criteria, we found that 41% of patients who had been diagnosed of CAN with the laboratory cut-off values had not been considered as dysfunctioning allografts by the physician, which indicates a clear underestimation of this important complication in the clinical practice. Furthermore, our results demonstrate that physicians tend to rely only on creatinine levels to estimate allograft function. It is widely accepted that serum creatinine alone is not an accurate index of GFR. Creatinine is a filtration marker whose clearance approximates GFR, its value is constant over time and among individuals and its measurement is reproducible across laboratories. Although the serum creatinine Several studies that assessed renal biopsies have shown that the use of serum creatinine levels to diagnose nephropathy may result in an underestimation of the severity of CAN [3, 6] . Biopsies have thus been considered a useful tool to diagnose renal dysfunction [10] . This has led to the recommendation of performing an allograft biopsy to all patients that show a sustained increase in serum creatinine !20% in the last 3-6 months, independently of proteinuria levels [11] . In our study, only 31.1% of patients with CAN according to physician's criterion had a biopsy performed, the degree of proteinuria being the main determinant for performing one. We also found that anti-proteinuric treatment with ACE/ ARB was associated with a delay in conducting a biopsy. This finding suggests that the reduction of proteinuria after the introduction of ACE/ARB may decrease clinician's awareness on the underlying renal injury and delays diagnostic decisions.
It has been documented that mild CAN (Banff Grade 1), is present in almost all renal allografts at the first year after renal transplantation and that severe rejection (Banff Grades 2 and 3) occurs in nearly 60% of renal allografts in a 10-year period [11] . In a survey conducted in Spain by Marcen et al. [12] which included 447 renal transplants, the prevalence of CAN with a creatinine clearance 59 mL/ min was 62.5% at 12 months, a bit higher than our estimated prevalence of 55% based on a more restrictive (50 mL/min) criteria in patients with longer follow-up. Another study conducted in Canada reported a kidney disease prevalence of 75% based on the same GFR criteria as Marcen et al., with a mean follow-up time of 7.7 years (very similar to ours) [13] . These results suggest that our findings are consistent with previous cohorts of renal transplant patients.
The main determinants for CAN in our study population were older donor age, hypertension and less immunosuppression in the immediate post-transplant period, as reflected by the association with the absence of induction therapy, cyclosporin use (with less powerful immunosuppressive action than tacrolimus) and, in tacrolimus-treated patients, lower levels at 1 year. These findings support an immunological origin of CAN, in accordance with some prospective evaluations [3] . We observed that patients who developed CAN already had worse renal function in the immediate post-transplant period, which suggests that pre-transplant factors are also involved.
Immunosuppressive treatment should be individually tailored according to individual immunological risks and adjusted for the varying clinical scenarios [5] . For instance, calcineurin inhibitors should be minimized in cases of chronic nephrotoxicity, or immunosuppression should be strenghthened in cases of subclinical or late rejection. One study that assessed the efficacy of immunosuppression modification in patients with CAN, found that cyclosporin minimization and addition of mycophenolate mofetil delayed the decline of graft function [14] . This approach was adopted in a small group of patients. Other clinical trials have demonstrated that the replacement of calcineurin inhibitors by proliferation signal inhibitors in stable patients results in an improvement of renal dysfunction and hypertension, without a significant increase in rejection incidence [15] . However, in our study, performance of a biopsy to diagnose CAN was not associated with an immediate modification in the immunosuppressive therapy. Only in those patients with a more pronounced increase in creatinine level, did the physicians consider more frequently the introduction of PSIs. Our results showed the heterogeneity concerning the management of biopsyproven CAN.
Our study has several strengths. The large number of patients and participating centres, with consecutive sampling procedure, is representative of the renal transplant population in Spain and may reflect the management of CAN in clinical practice. Despite the observational nature of the study, we were able to access medical records of past patient visits which enabled us to describe changes in renal function over time. On the other hand, our study also suffers from some potential limitations. The laboratory criterion for CAN was arbitrarily established choosing lower ranges of GFR from the CKD stages previously defined. However, the GFR data provides an upper limit for the real prevalence, which does not differ greatly according to previous studies [13] . We did not collect information about the type of donor (living or deceased), but according to data from the Spanish National Organization of Transplants, the percentage of living donors in our study population was quite small since this figure ranged from 0.8 to 3.9% of overall renal transplants in Spain between 1993 and 2005 [16] . The cross-sectional design does not allow us to establish causal relationships, although this was not the goal of the study, and all information collected from past visits was retrospectively collected and therefore subjected to potential bias.
In summary, our study shows that, after~8 years since renal transplantation, 55.5% of patients had CAN, which was considerably underestimated by physicians. An older donor age and less initial immunosuppression seem to be related to CAN development. Histological studies were performed in a low percentage of patients, and immunosuppressive changes were heterogeneous. More efforts should be made to improve CAN diagnosis and its management in the clinical practice to prevent its progression.
We think that defining more stringent guidelines to perform biopsies based on individual cases, early, when GFR begins to decline, even without proteinuria, should help to characterize the specific cause of renal injury and act in consequence in the best way according to the pathogenesis of the injury and the patient characteristics.
